4 recruiting, 3 active not recruiting, 3 unknown, 2 completed. 15 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Recruiting 4, Active not recruiting 3, Unknown 3, Completed 2, Terminated 2, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Small-cell Lung Cancer: new trials by email Literature Review of Small-cell Lung Cancer trials Research Report on Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer ZG006, Topotecan - Small-cell Lung Cancer | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 420 | 2025-12-12 | 2026-01-05 |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) ZL-1310, Investigator's Choice of Therapy - Small-cell Lung Cancer | Phase 3 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 480 | 2025-11-30 | 2026-10-16 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Tarlatamab, Durvalumab, Carboplatin - Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 350 | 2025-08-18 | 2026-09-08 |
| a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604 - Small-cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 636 | 2025-02-01 | 2025-02-11 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Tarlatamab, Durvalumab - Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 563 | 2024-06-05 | 2025-12-17 |
| SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC Experimental group (SRS/SRT/Hypo-RT), Controled group (HA-WBRT) - Small-cell Lung Cancer, Brain Metastases | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 340 | 2023-09-01 | 2026-10-08 |
| Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer Thoracic radiotherapy, Chemo-immunotherapy - Small-cell Lung Cancer | Phase 3 | Terminated | Norwegian University of Science and Technology | 239 | 2022-01-11 | 2026-01-28 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer Atezolizumab, Lurbinectedin, Carboplatin - Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 660 | 2021-11-18 | 2026-09-09 |
| The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. SHR-1316; Carboplatin; Etoposide；Radiotherapy, Palcebo; Carboplatin; Etoposide；Radiotherapy - Small-cell Lung Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 486 | 2021-01-22 | 2021-02-26 |
| PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study prophylactic cranial irradiation - Small-cell Lung Cancer | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 414 | 2019-07-01 | 2020-09-02 |
| Bioinformation Therapy for Lung Cancer Cancer ablation, Life information rehabilitation therapy - Small-cell Lung Cancer | Phase 2 / Phase 3 | Completed | Fuda Cancer Hospital, Guangzhou | 120 | 2017-09-02 | 2019-01-25 |
| Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer SIB-IMRT, routine IMRT - Small-cell Lung Cancer | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 350 | 2017-07-20 | 2021-02-01 |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX) - Small-cell Lung Cancer | Phase 3 | Completed | PharmaMar | 613 | 2016-08-30 | 2021-10-28 |
| Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) Amrubicin Hydrochloride - Small-cell Lung Cancer | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 130 | 2006-04-01 | 2022-04-12 |
Small Cell Lung Carcinoma (15) · Brain Neoplasms (2) · Carcinoma, Small Cell (1) · Lung Neoplasms (1) · Neoplasms (1)
Bronchial Neoplasms (15) · Carcinoma, Bronchogenic (15) · Lung Diseases (15) · Neoplasms by Site (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Lung Neoplasms (14) · Neoplasms (14) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Carcinoma (1)
Carboplatin (5) · Etoposide (3) · PM 01183 (3) · AMG 757 (2) · Topotecan (2) · atezolizumab (2) · durvalumab (2) · Cryosurgery (1) · Cyclophosphamide (1) · Doxorubicin (1) · EC regimen (1) · Electroporation (1) · Vincristine (1) · amrubicin (1)
Amgen (2) · Chinese Academy of Medical Sciences (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fuda Cancer Hospital, Guangzhou (1) · Hoffmann-La Roche (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Norwegian University of Science and Technology (1) · PharmaMar (1) · Qilu Pharmaceutical Co., Ltd. (1) · Sumitomo Pharma Co., Ltd. (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · SystImmune Inc. (1) · Zai Lab (Shanghai) Co., Ltd. (1)
China (9) · Germany (6) · Greece (6) · Italy (6) · Poland (6) · Spain (6) · United States (6) · Belgium (5) · France (5) · Hungary (5) · Netherlands (5) · Austria (4) · Czechia (4) · Japan (4) · Turkey (Türkiye) (4)
Drug Development Division (1) · Jason Wu (1) · Junliang Cai, MD (1) · Magnus Steigedal, PhD (1)
PMID 36252599, PMID 40473449, PMID 40934933
2023 (2)